Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Esperion Therapeutics, Inc. (ESPR) had Revenue of $168.45M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$168.45M
Net Income	$61.83M
Cost of Goods Sold	$27.85M
Gross Profit	$140.59M
Operating Expenses	$83.21M
Operating Income	$85.23M
Non-Operating Income/Expense	$-21.56M
Pre-Tax Income	$63.67M
Normalized Pre-Tax Income	$63.67M
Income after Taxes	$61.83M
Income from Continuous Operations	$61.83M
Consolidated Net Income/Loss	$61.83M
Normalized Income after Taxes	$61.83M
EBIT	$85.23M
EBITDA	$85.90M
Weighted-Average Shares Outstanding (Basic)	207.87M
Weighted-Average Shares Outstanding (Diluted)	207.87M
Earnings per Share (EPS) (Basic)	$0.32
Earnings per Share (EPS) (Diluted)	$0.32
Balance Sheet Financials
Current Assets	$462.57M
Property, Plant, and Equipment	$0.34M
Long-Term Assets	$3.32M
Total Assets	$465.89M
Current Liabilities	$300.81M
Long-Term Debt	$249.48M
Long-Term Liabilities	$467.04M
Total Liabilities	$767.85M
Common Equity	$-301.96M
Tangible Shareholders Equity	$-302.02M
Shareholders Equity	$-301.96M
Common Shares Outstanding	245.22M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-13.09M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$36.18M
Beginning Cash	$144.76M
End Cash	$167.85M
Increase/Decrease in Cash	$23.09M
Stock-Based Compensation	$9.87M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.54
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-4.75
Debt to Equity Ratio	-0.83
Gross Margin	83.46%
Operating Margin	50.60%
EBIT Margin	50.60%
EBITDA Margin	--
Pre-Tax Profit Margin	37.80%
Profit Margin	36.71%
Free Cash Flow	$-13.09M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.36
Inventory Turnover	0.27
Receiveable Turnover	1.20
Days Sales in Receivables	74.90
Return on Equity	-20.48%
Return on Tangible Equity	-20.47%
Return on Assets	13.27%
Return on Investments	-117.80%
Book Value Per Share	$-1.23
Free Cash Flow per Share	$-0.06
Operating Cash Flow per Share	$-0.06

Data from Zacks Investment Research, Inc.